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 Background: Pretransplant dialysis modality may affect outcome after simultaneous pancreas-kidney transplantation (SPKT), 
and it has been suspected that peritoneal dialysis (PD) is associated with more postoperative complications 
compared to hemodialysis (HD). The aim of this study was to evaluate whether pretransplant dialysis modality 
affects the risk for postoperative complications in SPKT recipients.
 Material/Methods: This was a retrospective longitudinal cohort study of all patients undergoing SPKT from 2010 to 2017, during 
which 99 simultaneous pancreas-kidney transplantations were performed. Three pre-emptive transplantations 
were excluded. Patient groups receiving PD (n=59) or HD (n=37) were similar regarding baseline characteristics. 
All complications occurring during the first 3 months after transplantation, as well as patient and graft survival, 
were analyzed.
 Results: There were no significant differences in postoperative complications between groups, with similar rates of intra-
abdominal infections (8% in HD vs. 10% in PD), pancreatitis (16% in HD vs. 17% in PD), gastrointestinal bleed-
ings (22% in HD vs. 10% in PD), and relaparotomies (27% in HD vs. 24% in PD). None of the patients had ve-
nous graft thrombosis. Past peritonitis was not associated with increased risk for postoperative complications 
in PD patients. Patient and graft survival were similar between PD and HD groups.
 Conclusions: Peritoneal dialysis is not a risk factor for postoperative complications after SPKT.
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Background
Simultaneous pancreas-kidney transplantation (SPKT) has es-
tablished its position in treating patients with type 1 diabe-
tes and end-stage renal disease [1–4]. It improves the progno-
sis [4–6] and quality of life [3,7] compared to kidney transplant 
alone (KTA). The restored glycemic control improves renal graft 
outcome in the long-term and can reduce secondary complica-
tions of type 1 diabetes [2,3]. However, surgical complications 
related to SPKT are common [8], even though there has been 
a significant decrease due to better identification of risk fac-
tors, improved surgical techniques, and better prophylaxis and 
immunosuppressive regimens [4,9]. Despite improved results in 
outcome and complications, the number of all pancreas trans-
plantations has decreased steadily from the beginning of the 
21st century until only just recently, taking a slight turn in SPKT 
and pancreas transplantation alone (PTA) [10]. The field of is-
let transplantation and artificial pancreas is evolving, and with 
that, the overall trend of pancreas transplantations, especially 
PTA and pancreas after kidney (PAK) transplantations, may 
continue to decline in the future [2]. For now, the improving 
results of pancreas transplantations encourage centers to al-
low more patients onto waiting lists, as there are still many 
barriers to overcome before islet transplantation and artificial 
pancreas use will replace this method.
It is unclear whether pretransplant dialysis modality affects out-
come. There are several studies comparing hemodialysis (HD) 
and peritoneal dialysis (PD) in patients receiving KTA [11–16], 
but few have focused on SPKT. It has been suspected that PD is 
associated with more surgical complications compared to HD, 
especially intra-abdominal infections leading to pancreas loss 
and vascular thrombosis [17], whereas a recent study found 
that pre-SPKT modality of dialysis did not influence the pa-
tient or graft survival nor did it increase the risk for surgical 
complications in SPKT patients [18]. In studies focusing solely 
on intra-abdominal infections after SPKT, no difference was 
detected between PD and HD patients [19,20] but the oppo-
site results have been reported previously, with PD as a pre-
disposing factor [21]. PD is still considered a contraindication 
for SPKT in some centers.
The primary aim of this study was to assess whether dialy-
sis modality affects the risk for early postoperative complica-
tions in SPKT recipients.
Material and Methods
We conducted a retrospective longitudinal cohort study at our 
institution, in which pancreas transplantations were started in 
2010. All consecutive recipients of pancreas transplantation 
between 2010 and 2017 were analyzed. Patient data were 
collected from the Finnish Transplant Registry, which is a na-
tional registry for the follow-up of kidney transplant patients, 
as required by law, and electronic patient records.
All transplantations were ABO-compatible and cytotoxic cross-
match-negative. Immunosuppression comprised tacrolimus, 
mycophenolate, and steroids. All patients received induction 
with single-dose antithymocyte globulin before transplanta-
tion. The post-transplantation trough level target for tacroli-
mus was 12–15 ug/ml for the first 14 days and 10–12 ug/ml 
for days 15–90 after transplantation. All transplantations were 
performed using enteric proximal jejunal exocrine drainage. 
The peritoneal catheter was always removed during surgery. 
Thrombosis prophylaxis was performed with dalteparin 2500 IU 
twice daily for the first 14 postoperative days and 2500 IU 
once daily for the next 14 days. This study was approved by 
the Institutional Review Board of Helsinki University Hospital 
(HUS/269/2017).
Complications occurring during the first 3 months after trans-
plantation were included. Post-transplantation pancreatitis and 
its severity was determined using the revised Atlanta classi-
fication [22]. Intra-abdominal infections were defined as the 
development of infected fluid collection that required an in-
tervention. The administration of anti-bacterial drugs without 
intervention was not included in this category. Among patients 
on PD, data on history of preoperative peritonitis were gath-
ered to analyze the possible association with post-transplant 
intra-abdominal infections. Gastrointestinal bleedings were 
defined as bleedings requiring relaparotomy or endoscopy, 
or patients suffering from sudden anemia combined with ei-
ther melena or hematemesis. Other bleedings, consisting of 
intra-abdominal hemorrhages, were diagnosed by CT scan or 
relaparotomy performed due to acute anemia.
The statistical analyses were done comparing patients in the 
PD group and HD group. Survival probabilities were estimated 
using the Kaplan- Meier method, with death with functioning 
graft, pancreas graft failure, and kidney graft failure as the 
events. Non-parametric statistical analyses were performed, 
as all distributions were not normal. Categorical data were an-
alyzed using Fisher’s exact test, and continuous variables were 
analyzed using the Mann-Whitney U test. Two-sided P value 
<0.05 was considered as statistically significant. The calcula-
tions were performed using IBM SPSS Statistics (version 21, 
IBM Corporation, Somers, NY). Data are expressed as mean 
±1 standard deviation.
Results
From March 2010 to December 2017, 101 pancreas transplan-
tations were performed: 99 patients received SPKT and were 
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all included, and 2 patients who received pancreas after kid-
ney transplantation (PAK) were excluded. Before transplanta-
tion, 59 patients had a history of PD: 52 patients were on PD 
at the time of transplantation, 7 patients were previously on 
PD but were converted to HD, and 37 patients had been ex-
clusively on HD. Pre-emptive transplantations (n=3) were not 
included in the comparative analysis (Figure 1).
There were no significant differences between the HD group and 
PD group regarding baseline characteristics such as recipient 
age, BMI, diabetes duration, dialysis duration, HLA-mismatch, 
or cold ischemia time. Also, donor characteristics were similar 
between groups. The mean follow-up time was 29±20 months 
for the HD group and 32±22 months for the PD group (Table 1).
During the follow-up, 3 patients died, all in the PD group. 
The causes of death were myocardial infarction 45 months af-
ter transplantation, pulmonary embolism 8 months after trans-
plantation, and complicated atypical mycobacterial infection 
combined with pancreatitis of the patient’s native pancreas, 
which occurred 4 months after transplantation. All other kid-
ney transplants were functioning at end of follow-up. Three 
pancreas grafts were removed due to infectious causes within 
2 months after transplantation – 2 in the HD group and 1 in 
the PD group; these 3 patients were all alive with a function-
ing kidney graft at the end of follow-up. No significant differ-
ences were detected in kidney or pancreas graft or patient 
survival between the groups. Pancreas graft survival data are 
shown in Figure 2. Five patients developed insulin resistance 
during follow-up: 4 patients were managed by oral diabetes 
medication (metformin or sitagliptin) and 1 patient required 
exogenous insulin therapy.
All early postoperative complications are compared in Table 2. 
There were no significant differences in the frequency of com-
plications between the HD and PD groups.
After transplantation, 9 patients had an intra-abdominal infec-
tion, with no significant difference between HD and PD groups 
(8% vs. 10%). Microbiological diagnosis was reached in all 
9 cases; there were 4 bacterial infections, 1 fungal infection, 
101 pancreas
transplantations
99 SPKT
2 pancreas after
kidney
transplantations
3 pre-emptive
transplantations
7 previously on
PD, HD at tx52 on PD at tx 37 on HD at tx
Figure 1.  Flow-chart of the patients included. 
SPKT – simultaneous pancreas and kidney 
transplantation; HD – hemodialysis; PD – peritoneal 
dialysis; Tx – transplantation.
HD (n=37) PD (n=59)  P-value
Follow up time (months) 29±20 32±22 0.46
Recipient age (years) 42±9 43±8 0.39
Recipient BMI 25±3 24±2 0.16
Diabetes duration (years) 32±9 33±8 0.74
Dialysis duration (months) 13±9 13±8 0.74
Donor age (years) 40±13 38±13 0.35
Donor BMI 24±2 24±3 0.51
HLA AB mismacth 2.7±1.0 2.7±1.0 0.84
HLA DR mismatch 1.5±0.7 1.4±0.6 0.23
Kidney cold ischemia (hrs) 10.2±1.9 10.1±1.9 0.89
Pancreas cold ischemia (hrs) 8.1±1.8 8.2±1.9 0.76
Length of hospital stay (days) 21±9 22±15 0.72
1 Year creatinine (mg/dL) 1.2±0.3 1.3±0.4 0.46
End of follow up creatinine (mg/dL) 1.3±0.7 1.2±0.4 0.39
Table 1. Pretransplant recipient and donor characteristics.
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and 4 were cultured positive for both bacteria and fungi. Intra-
abdominal infection was complicated with graft pancreatitis 
in 7 cases (HD group 8% vs. PD group 7%) and relaparotomy 
was required. Additionally, 2 patients, both in the PD group, 
had a wound infection that required vacuum-assisted closure 
and antibiotic therapy.
We analyzed also the impact of previous peritonitis among 
PD patients. Fifteen patients had a history of peritonitis dur-
ing dialysis, with 7 patients experiencing 2 or more episodes. 
History of peritonitis was not associated with increased risk 
of complications, as after transplantation only 1 of these pa-
tients had an intra-abdominal infection and 1 patient had 
mild pancreatitis. Among patients converted from PD to HD 
(n=7), 3 were converted because of recurrent peritonitis, 3 had 
a pleuroperitoneal leak, and 1 had insufficient ultrafiltration. 
No differences were recorded in surgical conditions or time 
of surgery between patients with or without history of peri-
tonitis (data not shown).
Relaparotomy rates were similar between groups (27% in the HD 
group and 24% in PD group). When the reasons for relaparotomy 
were analyzed, gastrointestinal bleedings (11% in HD group vs. 
5% in PD group), other major bleedings (5% in HD group vs. 8% 
in PD group), and intra-abdominal infections (8% in HD group vs. 
7% in PD group) were identified as the main causes. All indica-
tions for relaparotomy are summarized in Table 2.
The rate of bleeding complications was also similar between 
the groups. A nonsignificantly higher proportion of HD patients 
experiencing gastrointestinal bleeding compared to PD patients 
(22% vs. 10%, p=0.15) was identified. Other major bleedings 
(8% in HD group and 17% in PD group) consisted mostly of he-
matomas (in 8/13 patients) surrounding the renal transplant.
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Figure 2.  Pancreas graft survival (N=96, p=0.59). Kaplan-
Meier estimates for pancreas graft survival. 
HD – hemodialysis; PD – peritoneal dialysis.
HD (n=37) PD (n=59) P-value
Delayed graft function  5 (14%)  5 (9%) 0.5
Biopsy-proven acute rejection
 Kidney
 Duodenum
 Pancreas
 4 (11%)
 6 (16%)
 2 (5%)
 4 (7%)
 3 (5%)
 2 (3%)
 0.7
 0.08
 0.64
Relaparotomy
 Intra-abdominal infection
 Pancreatitis
 Gastrointestinal bleeding
 Other bleeding
 Ureteral stricture
 10 (27%)
 3 (8%)
 0 (0%)
 4 (11%)
 2 (5%)
 1 (3%)
 14 (24%)
 4 (7%)
 2 (3%)
 3 (5%)
 5 (8%)
 0 (0%)
0.81
Gastrointestinal bleeding  8 (22%)  6 (10%) 0.15
Other major bleeding  3 (8%)  10 (17%) 0.36
Intra-abdominal infection  3 (8%)  6 (10%) 1.0
Pancreatitis
 Mild
 Moderate
 Severe
 6 (16%)
 2 (5%)
 3 (8%)
 1 (3%)
 10 (17%)
 2 (3%)
 5 (9%)
 3 (5%)
1.0
Table 2.  Comparison of complications after pancreas-kidney transplantation between patients on hemodialysis (HD) or peritoneal 
dialysis (PD) before transplantation.
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No differences were detected between groups when the rates 
of acute rejection or delayed graft function (DGF) were com-
pared between the groups (Table 2). None of the patients had 
graft thrombosis.
Discussion
There are large worldwide differences in the usage of PD. 
In countries belonging to the ERA-EDTA (European Renal 
Association – European Dialysis and Transplant Association) 
registry, the prevalence of PD varies from 3.7% to 21.9% 
among patients on long-term dialysis [23]. In these countries, 
the prevalence of PD has been declining, although initiating 
PD was associated with improved patient survival compared 
to HD [24]. Also, in the United States, the use of PD has been 
declining, with 10% of patients on long-term dialysis currently 
being treated with PD [25]. In Finland, according to the latest 
report, the prevalence of PD is 19% of patients on long-term 
dialysis [26].
When evaluating patients undergoing SPKT, in our study, 62% 
(59/96) of patients had a history of PD before transplantation. 
This high incidence could be due to the fact that SPKT patients 
are younger and healthier compared to all ESRD patients, and 
they often choose a home dialysis modality as an autonomous 
method of renal replacement therapy. Center experience, geo-
graphical factors, and possible vascular problems also have an 
impact when choosing between HD and PD. In other studies, 
the percentage of patients on PD before SPKT is reported to 
be 25–41% [17,18,20].
Our study showed no significant differences in postoperative 
complications among patients undergoing SPKT when com-
paring HD or PD as pretransplant dialysis modalities. The rate 
of intra-abdominal infections, relaparotomies, pancreatitis, 
bleeding complications, and graft rejection were similar be-
tween groups. Graft survival was also similar between HD and 
PD groups, with 3 pancreas grafts removed due to infectious 
causes (2 in the HD group and 1 in the PD group). Although 
all 3 deaths occurred in the PD group, one was due to pulmo-
nary embolism and another was due to myocardial infarction; 
these deaths occurred late after transplantation and were eval-
uated as unrelated to previous dialysis modality.
The effect of dialysis duration on mortality in ESRD patients 
is discussed with variable results. According to many studies, 
within the first year or two of dialysis, PD is associated with 
superior survival over HD, whereas in the longer term, PD is as-
sociated with comparable or increased mortality rates [27–29]. 
In our study, both groups had moderately short mean dialysis 
times before transplantation.
Controversy exists in previous studies about whether PD is a risk 
factor for intra-abdominal infections. Some studies report no 
difference between dialysis modalities [18–20], whereas other 
studies suggest that PD may be a risk factor for intra-abdom-
inal infections in SPKT patients [17,21]. Our results showed 
no difference between groups with regard to intra-abdominal 
infections (8% for HD and 10% for PD). Furthermore, no in-
creased risk for intra-abdominal infections was seen among 
patients with a previous history of peritonitis or in patients 
with several episodes of past peritonitis.
Another feared complication often leading to pancreas graft loss 
after transplantation is graft thrombosis. Some studies suggest 
PD as a risk factor for graft thrombosis among kidney transplant 
recipients [15,16]. In a recent study comparing SPKT patients, 
a higher relaparotomy rate due to graft thrombosis was detected 
in the PD group [17]. In our study, none of the patients expe-
rienced graft thrombosis. Our strategy of using an aggressive 
approach with postoperative anticoagulation could be the rea-
son for the lack of thrombosis, but increasing the risk for bleed-
ing complications, which were relatively frequent in our cohort.
Our study has some limitations that should be considered. As our 
center is the only transplant center in Finland, this a single-center 
study, although it represents a whole nation-wide cohort. In addi-
tion, no specific rating system was used to rate our donors, which 
makes comparison to other centers somewhat difficult. Therefore, 
these results may not be applicable to other transplant popula-
tions. On the other hand, our findings support the findings of re-
cent studies suggesting that PD is a safe dialysis modality, even 
among patients waiting for SPK transplantation. In addition, our 
study is limited by the small number of patients. The strengths 
of our study include the high frequency of PD treatment in our 
country, and the fact that both PD and HD groups were very simi-
lar with regard to baseline characteristics. In addition, all patients 
received a transplant within a short time period, during which no 
other changes occurred in treatment policies.
Conclusions
We found that peritoneal dialysis was not a risk factor for post-
operative complications after simultaneous pancreas-kidney 
transplantation, even among patients with a history of peri-
tonitis, and the pretransplant dialysis modality was not as-
sociated with patient or graft survival. Our findings, together 
with the previous literature, suggest that peritoneal dialysis 
is a safe dialysis modality for patients waiting for pancreas 
transplantation.
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